glasdegib
Sign in to saveAlso known as PF 04449913, PF-04449913, Daurismo
Glasdegib, sold under the brand name Daurismo, is a medication for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults older than 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy. It is taken by mouth and is used in combination with low-dose cytarabine.
Wikidata facts
- Mass
- 374.185509
Show 4 more facts
- isomeric SMILES
- CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N
- canonical SMILES
- CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N
- chemical formula
- C₂₁H₂₂N₆O
- half-life
- 17.4
Sources (9)
via Wikidata · CC0
~3 min read
Article
3 sectionsContents
- History
- References
- External links
Glasdegib, sold under the brand name Daurismo, is a medication for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults older than 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy. It is taken by mouth and is used in combination with low-dose cytarabine.
The recommended dose of glasdegib is 100 mg orally once daily on days 1 to 28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control.